Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis

被引:72
作者
Jain, Anjali [1 ]
Pooladanda, Venkatesh [2 ]
Bulbake, Upendra [1 ]
Doppalapudi, Sindhu [1 ]
Rafeeqi, Towseef Amin [3 ]
Godugu, Chandraiah [2 ]
Khan, Wahid [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharmaceut, Hyderabad, Andhra Pradesh, India
[2] Natl Inst Pharmaceut Educ & Res NIPER, Dept Regulatory Toxicol, Hyderabad, Andhra Pradesh, India
[3] Univ Kashmir Campus, Reg Res Inst Unani Med, Srinagar, Jammu & Kashmir, India
关键词
Thymoquinone; Psoriasis; Lipospheres; Inflammation; Imiquimod induced psoriatic plaque model; RAW; 264.7; MACROPHAGES; IN-VITRO; SKIN; FORMULATION; INFLAMMATION; COMBINATION; MODERATE; VIVO; IL-6; PSORALEN;
D O I
10.1016/j.nano.2017.06.009
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offers an effective mean of penetration along with stability and scalability. TMQ lipospheres of particle size below 70 nm were prepared and evaluated. These lipospheres resulted in deeper skin penetration, slow release and skin compatibility. Antiinflammatory and anti-psoriatic potential of lipospheres was determined using in vitro cell lines and imiquimod induced psoriatic plaque model. Cell lines studies indicated reduction in the level of nitric oxide and IL-2, IL-6, IL-1 beta, TNF-alpha, whereas in vivo results indicated improvement in the phenotypic, histopathological features and reduced level of IL-17 and TNF-alpha in psoriatic skin. These results suggest the potential of TMQ lipospheres in the management of psoriasis. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:2251 / 2262
页数:12
相关论文
共 46 条
[1]  
Ahmed Jawad H, 2014, J CLIN EXP INVEST, V5, P186, DOI DOI 10.5799/AHINJS.01.2014.02.0387
[2]  
[Anonymous], 2017, AB PSOR
[3]  
[Anonymous], ARTHRITIS RES THER, DOI DOI 10.1186/AR1917
[4]  
[Anonymous], 2013, ELECT J DIFFERENTIAL, DOI DOI 10.1371/J0URNAL.P0NE.0067078
[5]   Cyclosporin pro-dispersion liposphere formulation [J].
Avramoff, Avi ;
Khan, Wahid ;
Ezra, Aviva ;
Elgart, Anna ;
Hoffman, Amnon ;
Domb, Abraham J. .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :401-406
[6]  
Blalock TD, 2001, WOUNDS, V13, P35
[7]  
Christopher Penney LG, 2004, Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis, Patent No. [WO2004069237 A1, 2004069237]
[8]   CLINICAL-TRIALS OF TOPICAL CORTICOSTEROIDS IN PSORIASIS - CORRELATIONS WITH THE VASOCONSTRICTOR ASSAY [J].
CORNELL, RC .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1992, 31 :38-40
[9]   Is the prevalence of psoriasis increasing? A 30-year followup of a population-based cohort [J].
Danielsen, K. ;
Olsen, A. O. ;
Wilsgaard, T. ;
Furberg, A. -S. .
BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (06) :1303-1310
[10]   The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis [J].
Di Cesare, Antonella ;
Di Meglio, Paola ;
Nestle, Frank O. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (06) :1339-1350